Alnylam advances ATTR amyloidosis care with AMVUTTRA growth and new TTR therapy development

Alnylam Pharmaceuticals marked one year since AMVUTTRA's U.S. approval for ATTR cardiomyopathy, expanding treatment options for a larger patient group. The company continues to grow AMVUTTRA adoption globally while developing next-generation TTR therapy, nucresiran, aiming to improve outcomes further. Alnylam also invests in early diagnosis and coordinated care to enhance long-term patient results, reinforcing its leadership in RNAi therapeutics for ATTR amyloidosis.